Filling a gap so biotech startups can advance to the next level

By Samantha Black, PhD, ScienceBoard editor in chief

October 26, 2021 -- In the biotechnology industry, there is a need for capital among companies that are already commercial and have products with demonstrated success but that might not yet be profitable. BroadOak Capital fills the gap for biotech companies between venture capital (for startups) and private equity (for already profitable companies), according to BroadOak partner Bill Snider in an exclusive interview with Editor-in-Chief Samantha Black, PhD.

BroadOak Capital was founded in 2006 with the goal of staying in the biotechnology business while focusing on the research and diagnostics tools and services in the space. Research tools encompass everything in a lab, including low-tech instruments such as hoods and freezers to expensive analytical equipment and reagents, according to Snider. These tools are not regulated by the U.S. Food and Drug Administration (FDA) but are used to create products that are regulated by the FDA.

The company is also interested in investing in the pharmaceutical services industry, which could include good laboratory practice testing services, contract research organization services, or clinical trial and trial recruitment services.

"The products that might become a drug are innovative, but oftentimes they require an innovative tool that cracked an old problem that people were having a hard time getting around," Snider said.

Video loading ...

Over the last decade, BroadOak has made over 50 growth capital investments within the biotech space. The company continues to be focused on investing in research tools and services within the cell and gene therapy, single-cell analysis, and synthetic biology spheres.

When asked what advice he has for scientific entrepreneurs, Snider said, "View the financial community as a collaborator. When you are working on a hard problem, you want to bring on people with multiple expertise and diverse ways of thinking ... If you view them as a collaborator rather than someone who doesn't see the world the way you do, you end up with a mutually beneficial experience."

Do you have a unique perspective on your research related to biotech finance? Contact the editor today to learn more.


Machine Bio crowned as BioTools Innovator champion
CARLSBAD, CA - Machine Bio co-founder and CEO David Marash delivered an impassioned pitch that resulted in the protein synthesis company being named the...
BioTools Innovator announces final 5
BioTools Innovator has selected five accelerator companies to compete for the title of the first BioTools Innovator program winner. The finalists were...
BioTools Innovator selects 10 accelerator semifinalists
BioTools Innovator has selected 10 companies to participate in the organization's inaugural three-month virtual mentorship-focused accelerator program.

Copyright © 2021

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter